PARSIPPANY, NJ, Jan 17, 2012 (MARKETWIRE via COMTEX) --The Medicines Company (NASDAQ: MDCO) today announced publication in the Journal of the American Medical Association (JAMA) of clinical trial results from testing of cangrelor, an investigational intravenous antiplatelet.

The article, "Bridging Antiplatelet Therapy With Cangrelor in Patients Undergoing Cardiac Surgery," is available in the January 18 JAMA issue under Original Contributions.

About Cangrelor, About the BRIDGE Trial Cangrelor is an investigational intravenous small molecule antiplatelet agent not approved for commercial use in any market. BRIDGE is a prospective, randomized, double-blind, placebo-controlled multicenter trial which evaluated cangrelor or placebo in 210 patients with an acute coronary syndrome (ACS) or treated with a coronary stent and receiving a thienopryidine awaiting coronary artery bypass graft (CABG) surgery. The primary efficacy endpoint was platelet reactivity. The main safety endpoint was excessive CABG-surgery related bleeding. In October 2010, The Medicines Company initiated a Phase 3 clinical trial called PHOENIX to evaluate cangrelor in patients undergoing percutaneous coronary intervention (PCI).

About The Medicines Company The Medicines Company (NASDAQ: MDCO) provides medical solutions to improve health outcomes for patients in acute and intensive care hospitals worldwide. These solutions comprise medicines and knowledge that directly impact the survival and well-being of critically ill patients.